CTLA4 and basal cell carcinoma: The current DART cohort assesses the outcome of dual low-dose anti-CTLA-4 therapy and anti-PD-1 therapy, specifically utilizing the combination of ipilimumab and nivolumab, in the management of patients with metastatic basal cell carcinoma.